Oscient shrinks workforce by one-third; Alcon plans to lay off 260;

> Oscient Pharmaceuticals plans to slash one-third of its employees--100 of 305--in an effort to save cash and reduce its debt; the cuts will hit hardest on its sales team. Release l Report

> Alcon, an eye-care company headquartered in Fort Worth, said Wednesday sluggish U.S. drug sales and competition were prompting it to lay off 260 workers. Report

> Bayer Schering Pharma plans to strengthen its global R&D capabilities by investing €100 million into a global research center in Beijing, China. Report

> Johnson & Johnson subsidiary Centocor Ortho Biotech said a lower-dose formulation of anti-HIV med Prezista is now available for pediatric patients. Release

> Otsuka America Pharmaceutical appointed Mark Altmeyer as its president and CEO; previously, Altmeyer worked at Bristol-Myers Squibb as a senior vice president. Release

> Abbott received 510(k) clearance from the FDA for its new, compact hematology instrument, Cell-Dyn Emerald. Release

> Amid concerns of a possible human bird flu outbreak, China's Food and Drug Administration announced that the state has already begun building stockpiles of the human bird flu vaccine Panflu as a precaution. Eight cases of human bird flu have been reported since December, including five fatalities. Report

> Novartis Vaccines is reporting progress with a new meningitis B vaccine that could be on the market in two years. The company says the vaccine should be up for a license in Europe next year. Report

> CNN is reporting that a special court at the Justice Department will hand down a decision later today on whether certain vaccines cause autism. Report 

> Just a few days before Vertex CEO Joshua Boger (photo) announced plans to step down in May, he worked out a new "transition agreement" that's worth millions of dollars. Vertex will now hand over $2.85 million in cash in November while accelerating his stock vesting schedule and stock awards. Report

> Tustin, CA-based Peregrine Pharmaceuticals says its lead program, bavituximab, has hit its primary endpoint in a Phase II study for advanced breast cancer. Report

> The Malaysian government is backing its bid to broaden the country's biotech base with $3 billion for R&D and enhanced healthcare. And it believes that working more closely with Indian developers could be a key to its success. Report

> Belgium's ActoGenix has returned to the venture capital well for $17 million in fresh funds. The fledgling developer is a spin-off of VIB and Ghent University. And it says it expects to see a significant amount of new data on its two lead programs this year. Report

> Chicago-based Advanced Life Sciences has handed out pink slips to nearly a third of its staff as it concentrates its efforts on gaining an approval on a new antibiotic--cethromycin. Report

> Denmark's NeuroSearch says it's shelving a pain program after a mid-stage trial for the experimental pain med ABT-894 failed to deliver the data it was hoping for. Report

And Finally... Russian scientists working at a "graveyard" of extinct mammoths and woolly rhinos in Siberia claim to have found a bacterium that could prolong human virility and life span. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.